Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?

insidermonkey.com · 2026-10-13

Biogen Inc. (NASDAQ:BIIB) closed at $225.71 on October 9.

TickrTrends take: Biogen operates in a highly competitive Healthcare sector where it faces direct competition from similarly sized pharmaceutical peers like Amgen and Gilead. Given TickrTrends' current assessment that BIIB is overvalued, investors focused on valuation metrics should monitor whether competitive pressures from AMGN and GILD might further pressure Biogen's pricing power or market share in coming quarters. The comparative analysis between these three companies becomes particularly relevant for value-oriented investors seeking to identify which large-cap pharma name offers the most attractive entry point relative to its fundamental metrics.

Read the full story at insidermonkey.com →